Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.50    -0.50 (-0.10%)
Bid:
502.00
Ask:
503.00
Spread: 1.00 (0.199%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

8 Feb 2018 07:00

8 February 2018 – Tate & Lyle PLC

TRADING STATEMENT

Tate & Lyle issues the following trading statement for the three months ended 31 December 2017.

The Group saw volume momentum in its Speciality Food Ingredients and Bulk Ingredients divisions and remains on track to deliver progress in adjusted profit before tax in constant currency for the year ending 31 March 2018, in line with guidance.

In Speciality Food Ingredients, the core business delivered good volume growth, including a continuation of modest volume growth in North America. In Food Systems, profit improved although volume was lower. SPLENDA ® Sucralose performed as anticipated with profit in line with the comparative period. In the division overall, decisions taken in the first half, particularly to invest behind the longer term development of the business, will moderate profit growth in the second half.

In Bulk Ingredients, sweetener volume in North America grew and profit growth is currently expected to be robust for the financial year ending 31 March 2018. The 2018 calendar year bulk sweetener pricing round is now substantially complete with margins broadly in line with the previous year.

END

A conference call will be held today at 08.00am GMT, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Executive designate and Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 22 February 2018.

UK replay number: 0208 196 1998

Replay access PIN: 6346734

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 30 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA ® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2017, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com .

SPLENDA ® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180207005974/en/

Copyright Business Wire 2018

Date   Source Headline
29th Apr 20223:15 pmRNSListing and Trading Application
26th Apr 20224:00 pmRNSResult of Meeting
13th Apr 20222:00 pmRNSHolding(s) in Company
7th Apr 20225:30 pmRNSHolding(s) in Company
7th Apr 202211:00 amRNSCirc re. special dividend and share consolidation
5th Apr 20224:00 pmRNSHolding(s) in Company
4th Apr 20224:00 pmRNSDirector/PDMR Shareholding
1st Apr 20222:15 pmRNSDisposal completion
1st Apr 20222:00 pmRNSTotal Voting Rights
31st Mar 20227:00 amRNSAcquisition
24th Mar 20222:00 pmRNSHolding(s) in Company
24th Mar 202211:00 amRNSDirectorate Change
21st Mar 20222:00 pmRNSHolding(s) in Company
18th Mar 20223:30 pmRNSHolding(s) in Company
10th Mar 20222:00 pmRNSHolding(s) in Company
9th Mar 20222:00 pmRNSHolding(s) in Company
1st Mar 20229:22 amRNSTotal Voting Rights
18th Feb 20222:00 pmRNSHolding(s) in Company
17th Feb 20222:00 pmRNSHolding(s) in Company
14th Feb 20222:00 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSTrading Statement
10th Feb 20222:00 pmRNSHolding(s) in Company
9th Feb 20227:00 amRNSDirectorate Change
3rd Feb 20224:00 pmRNSHolding(s) in Company
1st Feb 20223:30 pmRNSHolding(s) in Company
21st Jan 20222:00 pmRNSHolding(s) in Company
17th Jan 20222:00 pmRNSHolding(s) in Company
12th Jan 20224:00 pmRNSHolding(s) in Company
10th Jan 20223:45 pmRNSChange of Registered Office
10th Jan 20223:40 pmRNSDirector/PDMR Shareholding
4th Jan 20224:00 pmRNSBlock listing Interim Review
10th Dec 20212:09 pmRNSHolding(s) in Company
9th Dec 20213:10 pmRNSDirector/PDMR Shareholding
1st Dec 20219:58 amRNSTotal Voting Rights
18th Nov 20214:15 pmRNSHolding(s) in Company
5th Nov 202111:45 amRNSDirector/PDMR Shareholding
4th Nov 20217:00 amRNSHalf-year Report
3rd Nov 20216:01 pmRNSDirectorate Change
29th Oct 202111:15 amRNSHolding(s) in Company
21st Oct 20214:45 pmRNSRestatement re Primary Products Disposal
18th Oct 20212:30 pmRNSHolding(s) in Company
13th Oct 202112:30 pmRNSHolding(s) in Company
6th Oct 20213:30 pmRNSHolding(s) in Company
6th Oct 202111:15 amRNSDirector/PDMR Shareholding
4th Oct 20212:30 pmRNSDirector/PDMR Shareholding
4th Oct 20217:00 amRNSTotal Voting Rights
30th Sep 202112:00 pmRNSResult of General Meeting
13th Sep 20214:30 pmRNSCircular re. KPS Partnership
1st Sep 20219:58 amRNSTotal Voting Rights
18th Aug 202110:10 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.